Photo taken from Dana-Farber’s Breast Oncology Center/X
Apr 8, 2024, 14:26
Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH
Dana-Farber’s Breast Oncology Center posted on X:
“We are leading a randomized Phase 2 trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (ATEMPT 2.0).”
Read further.
Source: Dana-Farber’s Breast Oncology Center/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18